Why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Clinical researchers at Princess Margaret Hospital (PMH) in Toronto, Canada believe they can now answer that baffling question.
Since prostate cancer screening increased, more older men are surviving the disease through Active Surveillance, aka “Watchful Waiting”
Older men who were diagnosed with prostate cancer after early 1990 and were treated with conservative management (“Watchful Waiting”) lived significantly longer than men in similar situation 10 or 20 years previous to that.
This is the finding of a large new study based on Medicare patients’ records. The study is published in September 15 issue of the Journal of the American Medical Association (JAMA) by a team at The Cancer Institute of New Jersey (CINJ).
For Low Risk Prostate Cancer, Personalized Monitoring An Option
Active surveillance may be a viable option for some men with prostate cancer. Regular tests and careful tracking of any changes in the patient’s disease risk over time are imperative to ensure good outcomes, according to researchers in Toronto presenting at the annual meeting of the American Urological Association (AUA).
Active Surveillance for Low-Risk Prostate Cancer Demands Careful Selection, Study Says
Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for some patients with early-stage prostate cancer.
Miami Team Finds Most Low-Risk Patients Stay Treatment-Free for Five Years
For men diagnosed with low-risk prostate cancer, active surveillance can be a sensible first step in managing the disease. Mark Solloway and a team of urologists at University of Miami Miller School of Medicine have reported on outcomes for a group of their patients.
For Slow Growing Prostate Cancer Delay May be Reasonable, Hopkins Study Finds
Delaying surgery — even for years — for patients with small, low-grade prostate cancer does not appear to increase the risk of the disease progressing to an incurable form, according to a 10-year Johns Hopkins Medicine study. This discovery could prevent over-treatment, the authors say.